My watch list
my.chemeurope.com  
Login  

651 Newest Publications in proceedings of the national academy of sciences current issue

rss
matching the following criteria

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival [Medical Sciences]

19-Apr-2016 | Jonas Kloepper; Lars Riedemann; Zohreh Amoozgar; Giorgio Seano; Katharina Susek; Veronica Yu; Nisha Dalvie; Robin L. ..., Proceedings of the National Academy of Sciences current issue, 2016

Inhibition of the vascular endothelial growth factor (VEGF) pathway has failed to improve overall survival of patients with glioblastoma (GBM). We previously showed that angiopoietin-2 (Ang-2) overexpression compromised the benefit from anti-VEGF therapy in a preclinical GBM model. Here we ...

more

Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors [Medical Sciences]

19-Apr-2016 | Geoffrey Wayne Krampitz; Benson M. George; Stephen B. Willingham; Jens-Peter Volkmer; Kipp Weiskopf; Nadine Jahchan; ..., Proceedings of the National Academy of Sciences current issue, 2016

Pancreatic neuroendocrine tumors (PanNETs) are a type of pancreatic cancer with limited therapeutic options. Consequently, most patients with advanced disease die from tumor progression. Current evidence indicates that a subset of cancer cells is responsible for tumor development, metastasis, and ...

more

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages [Medical Sciences]

19-Apr-2016 | Teresa E. Peterson; Nathaniel D. Kirkpatrick; Yuhui Huang; Christian T. Farrar; Koen A. Marijt; Jonas Kloepper; Meen ..., Proceedings of the National Academy of Sciences current issue, 2016

Glioblastomas (GBMs) rapidly become refractory to anti-VEGF therapies. We previously demonstrated that ectopic overexpression of angiopoietin-2 (Ang-2) compromises the benefits of anti-VEGF receptor (VEGFR) treatment in murine GBM models and that circulating Ang-2 levels in GBM patients rebound ...

more

Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy [Medical Sciences]

12-Apr-2016 | Yin Zhang; Yunlong Yang; Kayoko Hosaka; Guichun Huang; Jingwu Zang; Fang Chen; Yun Zhang; Nilesh J. Samani; Yihai Cao, Proceedings of the National Academy of Sciences current issue, 2016

Anti-VEGF–based antiangiogenic drugs are designed to block tumor angiogenesis for treatment of cancer patients. However, anti-VEGF drugs produce off-tumor target effects on multiple tissues and organs and cause broad adverse effects. Here, we show that vasculatures in endocrine organs were more ...

more

Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy [Medical Sciences]

12-Apr-2016 | Hong-Jun Li; Jin-Zhi Du; Xiao-Jiao Du; Cong-Fei Xu; Chun-Yang Sun; Hong-Xia Wang; Zhi-Ting Cao; Xian-Zhu Yang; Yan-H ..., Proceedings of the National Academy of Sciences current issue, 2016

A principal goal of cancer nanomedicine is to deliver therapeutics effectively to cancer cells within solid tumors. However, there are a series of biological barriers that impede nanomedicine from reaching target cells. Here, we report a stimuli-responsive clustered nanoparticle to systematically ...

more

Myofibroblasts are distinguished from activated skin fibroblasts by the expression of AOC3 and other associated markers [Medical Sciences]

12-Apr-2016 | Lin-ting Hsia; Neil Ashley; Djamila Ouaret; Lai Mun Wang; Jennifer Wilding; Walter F. Bodmer, Proceedings of the National Academy of Sciences current issue, 2016

Pericryptal myofibroblasts in the colon and rectum play an important role in regulating the normal colorectal stem cell niche and facilitating tumor progression. Myofibroblasts previously have been distinguished from normal fibroblasts mostly by the expression of α smooth muscle actin (αSMA). We ...

more

CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing [Medical Sciences]

05-Apr-2016 | Andrew J. Clark; Devin T. Wiley; Jonathan E. Zuckerman; Paul Webster; Joseph Chao; James Lin; Yun Yen; Mark E. Davis, Proceedings of the National Academy of Sciences current issue, 2016

Nanoparticle-based therapeutics are being used to treat patients with solid tumors. Whereas nanoparticles have been shown to preferentially accumulate in solid tumors of animal models, there is little evidence to prove that intact nanoparticles localize to solid tumors of humans when systemically ...

more

Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target [Medical Sciences]

29-Mar-2016 | Jennifer Town; Helio Pais; Sally Harrison; Lucy F. Stead; Carole Bataille; Wilawan Bunjobpol; Jing Zhang; Terence H. ..., Proceedings of the National Academy of Sciences current issue, 2016

The cell surface proteome of tumors mediates the interface between the transformed cells and the general microenvironment, including interactions with stromal cells in the tumor niche and immune cells such as T cells. In addition, the cell surface proteome of individual cancers defines biomarkers ...

more

Recognition of the disordered p53 transactivation domain by the transcriptional adapter zinc finger domains of CREB-binding protein [Biophysics and Computational Biology]

29-Mar-2016 | Alexander S. Krois; Josephine C. Ferreon; Maria A. Martinez-Yamout; H. Jane Dyson; Peter E. Wright, Proceedings of the National Academy of Sciences current issue, 2016

An important component of the activity of p53 as a tumor suppressor is its interaction with the transcriptional coactivators cyclic-AMP response element-binding protein (CREB)-binding protein (CBP) and p300, which activate transcription of p53-regulated stress response genes and stabilize p53 ...

more

Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas [Medical Sciences]

15-Mar-2016 | Saya H. Ebbesen; Maurizio Scaltriti; Carl U. Bialucha; Natasha Morse; Edward R. Kastenhuber; Hannah Y. Wen; Lukas E. ..., Proceedings of the National Academy of Sciences current issue, 2016

Loss of the tumor suppressor gene PTEN is implicated in breast cancer progression and resistance to targeted therapies, and is thought to promote tumorigenesis by activating PI3K signaling. In a transgenic model of breast cancer, Pten suppression using a tetracycline-regulatable short hairpin ...

more

Page 1 From 66
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE